Drug
Sotrastaurin clinical trials
Also written AEB071.
Includes 1 study of Sotrastaurin acetate.
- studies test it
- 18
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How studies write it
Studies that test it under each name
Name
Development codes
- AEB071
- 15
Studies by the year they started
18 studies that test it; most in 2007 (4)
| Year | Studies |
|---|---|
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 2
Novartis Pharmaceuticals (11) · Novartis (4) · Columbia University (1) · Array Biopharma, now a wholly owned subsidiary of Pfizer (1) · James Blachly (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses sotrastaurin is read from its arms, and is right about nine times in ten.
Testing it · 18
- Trial of AEB071 in Combination With BYL719 in Patients With MelanomaCompletedPhase 1Columbia UniversityNCT02273219Written as AEB071
- A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque PsoriasisCompletedPhase 2Novartis PharmaceuticalsNCT00885196Written as AEB071
- Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney TransplantationCompletedPhase 1/2Novartis PharmaceuticalsNCT00492869Written as AEB071
- Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative ColitisCompletedPhase 2Novartis PharmaceuticalsNCT00572585Written as AEB071
- Safety, Tolerability, and Efficacy of AEB071 in the Treatment of UveitisCompletedPhase 2NovartisNCT00615693Written as AEB071
- Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma PatientsCompletedPhase 1Novartis PharmaceuticalsNCT01430416Written as AEB071
- Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell LymphomaCompletedPhase 1Novartis PharmaceuticalsNCT01854606Written as AEB071
- Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell LymphomaTerminatedPhase 1Novartis PharmaceuticalsNCT01402440Written as AEB071
- Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant PatientsCompletedPhase 1/2Novartis PharmaceuticalsNCT00403416Written as AEB071
- 24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant PatientsTerminatedPhase 2Novartis PharmaceuticalsNCT00555789Written as AEB071
- Pharmacokinetic Study of AEB071 in Patients Following Liver TransplantationCompletedPhase 1NovartisNCT00545259Written as AEB071
- A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal MelanomaTerminatedPhase 1/2Array Biopharma, now a wholly owned subsidiary of PfizerNCT01801358Written as AEB071
- Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's TransformationWithdrawnPhase 2James BlachlyNCT02285244Written as sotrastaurin acetate
- Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant RecipientsCompletedPhase 2Novartis PharmaceuticalsNCT00820911Written as AEB071 300 mg b.i.d. / everolimus
- Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant RecipientsCompletedPhase 2Novartis PharmaceuticalsNCT00504543Written as AEB071
- CAEB071 Thorough QTc Study in Healthy VolunteersCompletedPhase 1Novartis PharmaceuticalsNCT01594255Written as sotrastaurin
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071CompletedPhase 1NovartisNCT00409929Written as AEB071
- Safety of AEB071 in Healthy Volunteers and to Compare the Ethnicity, Metabolic, and Safety Effects Between Caucasian and Japanese Healthy SubjectsCompletedPhase 1NovartisNCT00416546Written as AEB071
Codes
What other systems call sotrastaurin · ClinicalTrials.gg INT005491
- MeSH (NLM) C543528sotrastaurinOne source NLM
- UNII (FDA) 7I279E1NZ8SOTRASTAURINConfirmed FDA, NLM, Wikidata
- Wikidata Q26331952sotrastaurinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80630SotrastaurinOne source FDA
- DrugBank DB12369One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C543528 | sotrastaurin | One source NLM |
| UNII (FDA) | 7I279E1NZ8 | SOTRASTAURIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q26331952 | sotrastaurin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80630 | Sotrastaurin | One source FDA |
| DrugBank | DB12369 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.